Real‐world outcomes in circulating tumor DNA–detected isocitrate dehydrogenase 1–mutant cholangiocarcinoma: First‐line gemcitabine and cisplatin with versus without immunotherapy
Oct 2026· Cancer· Vol 132· 0 citations· 35 references
Medicine
TL;DR
This study evaluated outcomes with 1L GemCis versus GemCis + ICI in ctDNA‐identified IDH1‐mutant aCCA in ctDNA‐identified IDH1‐mutant aCCA.
Abstract
Comprehensive genomic profiling (CGP) is recommended for advanced cholangiocarcinoma (aCCA). Circulating tumor DNA (ctDNA) testing provides a noninvasive alternative with concordance to tissue. Standard first‐line (1L) therapy is gemcitabine and cisplatin (GemCis) with or without immune checkpoint inhibitors (ICIs). Data suggest that patients with isocitrate dehydrogenase 1 (IDH1) mutations may derive less benefit from ICIs. This study evaluated outcomes with 1L GemCis versus GemCis + ICI in ctDNA‐identified IDH1‐mutant (IDH1+) aCCA.
ABSTRACT This study characterized the genomic profile of esophageal squamous cell carcinoma (ESCC) via circulating tumor DNA (ctDNA) to identify predictive biomarkers for efficacy of definitive radiotherapy combined with systemic therapy. In this prospective cohort of 40 ESCC patients, 7 tumor tissues and 71 serial pla...
Shu-Tang Liu, Qi Wang, Chun Han et al.· Cancer Science· 0 citations
Follicular lymphoma is the most common indolent lymphoma and next ‐ generation sequencing (NGS) studies have identified recurrent mutations in chromatin ‐ modifying genes ( KMT2D, CREBBP, and EZH2 ).
C. Martínez-Laperche, Pilar Lancho-Lavilla, Antonio Gutiérrez et al.· HemaSphere· 0 citations
Patients with chemotherapy‐ and androgen receptor pathway inhibitor (ARPI)‐naïve metastatic castration‐resistant prostate cancer (mCRPC) have generally shown worse overall survival (OS) with abiraterone versus enzalutamide in claims database studies. Given limitations of claims data, analysis using detailed electronic...
D. George, J. Ivanova, M. Touya et al.· Cancer Medicine· 0 citations
It is suggested that baseline and early on-treatment multigene ctDNA carries prognostic information in advanced PDAC, although superiority over KRAS or CA19-9 was not established.
Gi-Ye-On Lee, J. W. Chun, Dong-eun Lee et al.· International Journal of Mol...· 0 citations
Immune checkpoint inhibitors (ICIs) are established across the treatment continuum of urothelial carcinoma of the bladder, yet most patients derive no durable benefit. This narrative review appraises candidate predictors of ICI benefit in bladder urothelial carcinoma, distinguishing prognostic from predictive biomarker...
D. Novacescu, Mihael Musta, Radu Căprariu et al.· Cancers· 0 citations
Biomarkers that predict and monitor response to platinum-based chemotherapy and PARP-inhibitor (PARPi) therapy remain an unmet need in BRCA-positive pancreatic ductal adenocarcinoma (PDAC). Furthermore, blood-based assays to classify tumor expression subtypes are limited. Cell-free DNA (cfDNA) 5-hydroxymethylcyto...
Ceyda Çoruh, M. Raitses-Gurevich, Y. Ning et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.